Recent reports from Washington have placed Denmark, alongside Germany and Japan, at the centre of a controversial American health policy shift. At the direction of President Donald Trump, Secretary of Health Robert F. Kennedy Jr. is evaluating a reduction in the US childhood vaccine scheduleâcurrently covering 18 vaccinesâciting international models as âthe gold standard of science and common sense.â
While flattering to the Danish system, this overture has been met with profound scepticism by experts on both sides of the Atlantic. The move reveals less about the viability of transplanting Nordic public health policy and more about the deepening politicisation of science in the United Statesâa trend with significant implications for global health governance and transatlantic relations.
Why Denmark? Understanding the Appeal
Denmarkâs childhood immunisation programme, managed by the Statens Serum Institut under the Ministry of Health, includes fewer vaccines than the US schedule. This reflects a tailored epidemiological approach in a country with high healthcare accessibility, uniform record-keeping, and strong public trust in health authoritiesâabove 80%, according to OECD metrics. The Danish model works because it is embedded in a holistic welfare system where preventive care is universally accessible.
The Analysis: A Misplaced Comparison
Anders Peter Hviid, Professor and Head of Department at the Statens Serum Institut, articulates the core issue: âThe US has greater challenges with infectious diseases, more population diversity, and a fractured healthcare system. Vaccines there also serve as a crucial safety net for children without consistent access to care.â
Indeed, the US faces resurgences of measles and whooping cough, with 2025 projected to be the worst measles year since 1992âdirectly linked to falling vaccination rates. Reducing the schedule without strengthening the healthcare safety net could worsen these outbreaks.
Kennedy Jr.âs approach appears ideologically, rather than epidemiologically, motivated. A longtime vaccine sceptic and former head of the organisation Childrenâs Health Defence, he dismissed the independent Advisory Committee on Immunization Practices (ACIP) in 2024, replacing vaccine experts with political appointees. This decoupling of policy from evidence-based committees marks a dangerous precedentânot just for the US, but as a case study in how institutional safeguards can be eroded.
Business and Systemic Implications
For Nordic readers, this is not merely a foreign policy curiosity. The instability of US health regulation affects multinational pharmaceutical investments, global vaccine distribution norms, and cross-border public health collaboration. Should US vaccination rates drop further, travel and trade health regulations may tighten, impacting internationally mobile professionals and companies.
Moreover, the episode highlights a core strength of the Nordic model: trust built through transparency, consistency, and expert autonomy. In an age of global misinformation, that trust is a social and economic asset.
Bringing the Reporting to Current Times
As of early 2025, most US states and private insurers continue to follow the pre-existing ACIP schedule, creating a patchwork implementation landscape. Legal challenges are expected if federal recommendations change. Meanwhile, the World Health Organization has reiterated support for nationally tailored, evidence-based schedulesâimplicitly critiquing politically driven revisions.
Conclusion: A Cautionary Tale
Denmarkâs system should inspire global learning, but not selective political cherry-picking. The Nordic model succeeds because of its ecosystemânot just its vaccine list. The American debate underscores how public health can become a theatre for political symbolism, with real human and economic costs.
For our next analysis, we will examine how Nordic pharmaceutical and public health technology firms are navigating increasingly politicised global health markets. Share your insights with us: connect@nordicbusinessjournal.com